Post-spinoff “New 3M” is rebuilding credibility: a margin-led turnaround with AI/EV connectivity upside—still shadowed by PFAS/AFFF legal tail risk.
Overview
3M is in a pivotal renewal following the April 1, 2024 spin-off of its healthcare segment into Solventum (SOLV), reframing the company as a more focused material-science innovator. The remaining portfolio spans Safety & Industrial (~46% of 2025 sales), Transportation & Electronics (~33%, framed as the late-2020s growth engine), and Consumer (~20% with strong brands but lower pricing power). The thesis rests on 3M’s large innovation platform (55,000+ technologies; ~30,000 patents) and the new CEO William Brown’s “3M Excellence” operating system aimed at reducing bureaucracy, improving supply reliability, and expanding margins. Early-2026 results show margin and EPS improvement despite modest sales recovery, while the market continues to price in residual PFAS/AFFF litigation uncertainty. Key positives include PFAS manufacturing exit (end-2025), strengthening innovation metrics (NPVI), and discounted valuation versus industrial peers; key watch items are late-2026 bellwether trials and sustaining operational gains.